In May 2019, Bicycle formed a collaboration with the Dementia Discovery Fund (DDF) to use Bicycle technology for the development of novel therapeutics for neurodegenerative diseases. DDF is a specialized venture capital fund focused on discovering and developing novel therapies for dementia. Under the terms of the agreement, Bicycle will identify Bicycles that bind to clinically validated dementia targets. If promising lead compounds are identified, Bicycle and DDF have the option to jointly establish a new company to further develop those compounds. In October 2019, the collaboration was expanded to include Oxford University’s ARUK Oxford Drug Discovery Institute, one of three institutes within the Alzheimer’s Research UK Drug Discovery Alliance and an expert in diseases of the central nervous system.